Hims & Hers Health: Leaving GLP-1s Behind

Core Insights - Hims & Hers (HIMS) stock has experienced a significant decline of 58% since the initial coverage in January, indicating a shift in market perception and potential undervaluation of the company’s other segments beyond GLP-1s [1] Company Analysis - The investment thesis suggests that the market is overly focused on GLP-1s, potentially overlooking other growth opportunities within Hims & Hers [1] - The company is positioned in a sector that may benefit from a broader range of products and services, which could enhance its growth trajectory if recognized by investors [1] Investment Philosophy - The analysis emphasizes a GARP (Growth at a Reasonable Price) approach, seeking companies with sustainable growth potential that are undervalued [1] - A focus on fundamental analysis and unit economics is highlighted as essential for assessing long-term viability, suggesting that financial integrity is crucial for investment decisions [1]